The role of plasminogen activator inhibitor-2 in pneumococcal meningitis

Nina C Teske1,2,3, Joo-Yeon Engelen-Lee2,3, Susanne Dyckhoff-Shen1

  • 1Laboratory of Neuroinfectious Diseases, Department of Neurology, Klinikum Großhadern, Ludwig-Maximilians University, Munich, Germany.

Insights

Plasminogen activator inhibitor-2 (PAI-2) is elevated in pneumococcal meningitis, and its deficiency worsens brain pathology and mortality. PAI-2 plays a crucial role in regulating inflammation during this severe infection.

Area of Science:

  • Neuroscience
  • Immunology
  • Infectious Diseases

Background:

  • Pneumococcal meningitis involves coagulation cascade dysregulation.
  • Cerebral plasminogen activator inhibitor-2 (PAI-2) mRNA is upregulated during pneumococcal meningitis.
  • The precise role of PAI-2 in meningitis remains unclear.

Purpose of the Study:

  • To investigate the function of SERPINB2 (encoding PAI-2) in bacterial meningitis.
  • To analyze PAI-2's role in a pneumococcal meningitis mouse model and in vitro.
  • To determine the impact of PAI-2 deficiency on meningitis outcomes.

Main Methods:

  • Analysis of PAI-2 in cerebrospinal fluid (CSF) from human patients.
  • Functional, histopathological, and molecular analyses in a murine pneumococcal meningitis model using Serpinb2 knockout mice.
  • In vitro studies using wild-type and PAI-2-deficient bone marrow-derived macrophages (BMDMs).

Main Results:

  • PAI-2 concentration significantly increased in human CSF during pneumococcal meningitis.
  • PAI-2 deficiency in mice led to increased mortality and cerebral hemorrhages.
  • Serpinb2 knockout mice showed elevated C5a and reduced IL-10 levels in the brain.
  • In vitro, PAI-2 deficiency in BMDMs resulted in decreased IL-10 release.

Conclusions:

  • PAI-2 is elevated in human and murine pneumococcal meningitis.
  • PAI-2 deficiency disrupts inflammatory balance, exacerbating brain pathology and mortality.
  • PAI-2 plays a protective role in mitigating inflammation and improving outcomes in pneumococcal meningitis.

Related Concept Videos

Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
429
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
31
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
609
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
247